A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases: Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
Jonathan W. Riess(University of California Davis Medical Center), Heather A. Wakelee(Palo Alto Institute), Seema Nagpal(Stanford Medicine), Joel W. Neal(Stanford Medicine), Jonathan W. Kim(Children's Hospital of Los Angeles), Millie Das(VA Palo Alto Health Care System)
Cited by 14
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805